NUCLEIX Trademark

Trademark Overview


On Tuesday, March 21, 2023, a trademark application was filed for NUCLEIX with the United States Patent and Trademark Office. The USPTO has given the NUCLEIX trademark a serial number of 97848574. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Thursday, January 4, 2024. This trademark is owned by Nucleix Limited. The NUCLEIX trademark is filed in the Chemical Products, Pharmaceutical Products, Medical Instrument Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

Diagnostic test kits for medical and clinical use comprised of reagents for use in identifying and measuring changes associated with cancer, precancerous conditions or chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; medical diagnostic assay kits comprised of reagents for use in identifying and measuring changes associated with cancer, precancerous conditions or chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; medical diagnostic kits comprised of medical diagnostic reagents and assays for use in the field of cancer detection or detection of or chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; diagnostic reagents for medical purposes

Biochemical reagents for non-medical purposes; diagnostic preparations and reagents for scientific or research use; chemical and diagnostic preparations for clinical or medical laboratory use

Consulting services in the field of health; consulting services in the field of diagnostic medical testing; medical analysis for the diagnosis of cancer and chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease and prognosis of expected progression of the diseases; medical testing for diagnostic or treatment purposes in the fields of the detection and treatment of cancer and chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; providing cancer screening services; providing screening services for chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; providing a website featuring information in the fields of the diagnosis and treatment of cancer and chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease

Apparatus for medical diagnostic testing in the field of cancer or chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease

Pharmaceutical research and development; consulting services in the fields of biotechnology and pharmaceutical research and development; custom design and development of chemical reagents and biochemical assays
nucleix

General Information


Serial Number97848574
Word MarkNUCLEIX
Filing DateTuesday, March 21, 2023
Status641 - NON-FINAL ACTION - MAILED
Status DateThursday, January 4, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Description of MarkThe mark consists of the term NUCLEIX in a stylized format with the letter "I" inverted such that the dot appears below the word.
Goods and ServicesDiagnostic test kits for medical and clinical use comprised of reagents for use in identifying and measuring changes associated with cancer, precancerous conditions or chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; medical diagnostic assay kits comprised of reagents for use in identifying and measuring changes associated with cancer, precancerous conditions or chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; medical diagnostic kits comprised of medical diagnostic reagents and assays for use in the field of cancer detection or detection of or chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; diagnostic reagents for medical purposes
Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and ServicesBiochemical reagents for non-medical purposes; diagnostic preparations and reagents for scientific or research use; chemical and diagnostic preparations for clinical or medical laboratory use
Goods and ServicesConsulting services in the field of health; consulting services in the field of diagnostic medical testing; medical analysis for the diagnosis of cancer and chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease and prognosis of expected progression of the diseases; medical testing for diagnostic or treatment purposes in the fields of the detection and treatment of cancer and chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; providing cancer screening services; providing screening services for chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; providing a website featuring information in the fields of the diagnosis and treatment of cancer and chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease
Goods and ServicesApparatus for medical diagnostic testing in the field of cancer or chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease
Goods and ServicesPharmaceutical research and development; consulting services in the fields of biotechnology and pharmaceutical research and development; custom design and development of chemical reagents and biochemical assays

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateWednesday, April 12, 2023
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, April 12, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateWednesday, April 12, 2023
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, April 12, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, April 12, 2023
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNucleix Limited
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressRehovot 7670203
IL

Trademark Events


Event DateEvent Description
Monday, March 4, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, January 4, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, January 4, 2024NON-FINAL ACTION E-MAILED
Thursday, January 4, 2024NON-FINAL ACTION WRITTEN
Wednesday, December 13, 2023ASSIGNED TO EXAMINER
Wednesday, April 12, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, March 24, 2023NEW APPLICATION ENTERED